Niagen Bioscience is advancing NB4168, an oral candidate for Ataxia Telangiectasia, through preclinical development with contract partner Evotec. Nonclinical studies show NB4168 achieves substantially higher blood exposure than NR chloride, positioning the compound for IND submission and clinical evaluation.
Key Points
- NB4168 demonstrates superior pharmacokinetic profile versus NR chloride
- Rare Pediatric Disease and Orphan Medicinal Product designations secured
- IND-enabling studies underway; human trials planned within regulatory pathway
Longevity Analysis
NB4168 targets Ataxia Telangiectasia, a rare genetic disorder affecting DNA repair and accelerating age-related decline across multiple systems. The compound's improved bioavailability over existing NAD precursors suggests better capacity to support cellular energy production and regenerative capacity at therapeutically relevant doses. If clinical data supports efficacy, this represents a pathway toward addressing a condition where metabolic dysfunction and impaired cellular signaling drive premature aging phenotypes.
Original published by LT Wire.